Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9373MR)

This product GTTS-WQ9373MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9373MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15706MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ10390MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ1346MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ1740MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14904MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ6874MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ12035MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ5264MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW